English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 24 January 2017, 18:43 JST
Share:
    

Source: Eisai
Eisai Selected for Excellence in Sustainability Performance and Industry Mover Distinction by Robecosam

TOKYO, Jan 24, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for excellence in sustainability performance by RobecoSAM AG, a leading assessor of Social Responsibility Investment (SRI). Eisai has also been selected for the Industry Mover distinction in the pharmaceutical industry category, for achieving the
largest proportional improvement in its sustainability performance compared to the previous year.

Every year, RobecoSAM assesses major companies from around the world based on economic, environmental and social criteria. The top companies are showcased in The Sustainability Yearbook, an important indicator of environmental, social and governance (ESG) performance. This year, 2,473 companies from 60 industries were assessed. In each industry, companies that fall in the top 15%, and have scored at least 70% of the industry's top performing company's score, are selected for excellence in sustainability performance. Within the pharmaceutical industry category, 62 global companies were assessed, and 12 companies, including Eisai, were selected for excellence in sustainability performance.

In addition, Eisai has been selected for membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), as well as the FTSE4Good Index Series. Both are families of premier global indices for SRI.

The Eisai Group's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Guided by this philosophy, Eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Thursday, 18 April 2024, 10:53 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Wednesday, 17 April 2024, 16:17 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
2024年4月17日 10時00分 JST
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売
Wednesday, 3 April 2024, 16:24 JST
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Monday, 1 April 2024, 9:39 JST
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575